The steep cost of Sovaldi—Gilead Sciences’ $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs and whether the government should take more steps to regulate the cost of potentially life-saving treatments.
“The Sovaldi example has brought us to a crossroads,” said Karen Ignagni, president and CEO of the trade industry group America’s Health Insurance Plans, during a healthcare forum in Washington on Wednesday. “We need to sit together to begin talking about how we can attack this problem together before the government has to. … We cannot sustain six-figure therapies and we’re at the beginning of that trend.”
Read More